Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,501–1,600 of 3,116
Ascandar, N. E., Boadu, C., Stepman, G., et al. (2025) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1960 · Cited by 2
Diabetes and cancer: Doubts of a causal link
Renehan, A. G., Tipping, O., & Wang, M. (2024) · International Journal of Cancer · doi:10.1002/ijc.34862 · Cited by 2
Update on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists
Virk, A., & Allison, K. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062464 · Cited by 3
“Additionally, studies have found cardiovascular risk reduction due to GLP-1 medication use as well [14,15].”
Yoshimitsu, Y., Awaya, T., Kawagoe, N., Kunimasa, T., Iijima, R., & Hara, H. (2024) · Diseases · doi:10.3390/diseases12110297 · Cited by 2
Obesity management: a foundational cardiovascular health priority
Ostrominski, J. W., Plutzky, J., Sattar, N. A., Vaduganathan, M., & Aroda, V. R. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf043 · Cited by 4
Self-citationBelančić, A., Şener, Y. Z., Vučković, M., Blais, J. E., Fajkić, A., Sher, E. K., Radić, M., & Radić, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70378 · Cited by 4
A novel high dimensional approach to assess heterogeneous treatment effect in claims data
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf127 · Cited by 3
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
The Patient’s Journey in Obesity within the United States: An Exercise of Resilience against Disease
Northam, K. A., Hinds, M., Bodepudi, S., & Stanford, F. C. (2024) · Life · doi:10.3390/life14091073 · Cited by 4
Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
Schiele, F., Diévart, F., Jacobi, D., Angoulvant, D., Czernichow, S., Puymirat, É., Sabouret, P. F., & Aboyans, V. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100987 · Cited by 2
Lehenbauer, K. S., Nelson, A. J., Nodari, S., Sverdlov, A. L., & Harrington, J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10579-y · Cited by 5
Tom-Ayegunle, K., Tom-Ayegunle, O., Okoye, S., Chukwuemeka, U., Adeyina, T., Babarinde, A. O., & Eleam, U. (2026) · Cureus · doi:10.7759/cureus.100947 · Cited by 5
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
Chopra, H., Mehta, A., Ponde, C., Nanda, N. C., Wander, G., Oomman, A., KERKAR, P., Routray, S., Ratnaparkhi, G., Advani, P., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1375 · Cited by 2
Pantazopoulos, D., Vas, P. R. J., Rerkasem, K., & Παπάνας, Ν. (2026) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346261474199 · Cited by 3
The User’s Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Butalia, S., BAJAJ, H. S., Jain, R., Leung, K., Mansell, K. D., Reichert, S. M., Senior, P. A., & Shah, B. R. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.003 · Cited by 4
Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos
Pérez, J. S., & Miguel, G. A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103074 · Cited by 8
Menopause and Metabolic Syndrome
Agrawal, S., Panda, S., & Kashibhatla, J. (2024) · Springer eBooks · doi:10.1007/978-981-96-0239-1_13 · Cited by 2
Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
Scalia, I. G., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Farina, J., Pereyra, M., Lee, K. S. S., Tamarappoo, B. K., Arsanjani, R., & Ayoub, C. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00381-y · Cited by 6
Effectiveness of Semaglutide in Overweight or Obese Patients With IgA Nephropathy Without Diabetes
Si, F., Tang, C., Chen, P., Hou, W., Yang, H., Lv, J., Shi, S., Zhou, S., Liu, L., & Zhang, H. (2025) · Nephrology · doi:10.1111/nep.70023 · Cited by 2
Marshall, W. R., McDonnell, T., Green, D., Sinha, S., & Kalra, P. A. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106592 · Cited by 9
Nanna, M. G., Mena‐Hurtado, C., Divino, V. M., Zhao, Z., Chen, Y., Boland, J., Song, J., Traina, A. N., Özer, K., Knop, F. K., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70686 · Cited by 2
“…cardiovascular death, MI and stroke—by 20% compared with placebo (hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.72–0.90) in patients with established cardiovascular disease (MI, stroke and/ or symptomatic peripheral arterial disease [PAD]) and over-weight or obesity without diabetes [9].”
InfluentialIs semaglutide a target therapy for acquired hypothalamic obesity?
Prodam, F. (2024) · Pituitary · doi:10.1007/s11102-024-01443-7 · Cited by 2
Ahmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“In this study, GLP-1 receptor agonists were associated with improved lipid profiles, decreased levels of C-reactive protein, decreased waist circumference, and improved glycemic control [147].”
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
Dhamelia, P. M., Khandekar, N., Vallurupalli, S., Saucedo, J., Arthur, J. M., Jadvani, D., Beemidi, V. R., & Jain, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07897-0 · Cited by 2
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Oliveira-Gomes, D. D., Pingili, A., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001225 · Cited by 2
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 7
“Serious risks involve thyroid C-cell tumors (boxed warning) [45], pancreatitis, gallbladder disease, acute kidney injury (AKI), diabetic retinopathy, increased heart rate, and mood changes, including suicidal ideation [50].”
Davis, J. P. E., Henry, Z., Sharma, P., Tsunoda, S. M., Han, H., Orandi, B. J., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., Argo, C. K., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.10.008 · Cited by 3
Clinical and preclinical obesity: cardiovascular implications of a new diagnostic paradigm
Nam, G. E. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e6 · Cited by 4
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 3
Dziewierz, A., Rajtar-Salwa, R., Szarpak, L., Sojda, A., & Siudak, Z. (2025) · Archives of Medical Science · doi:10.5114/aoms/209719 · Cited by 2
Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few
Liuzzo, G., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad823 · Cited by 2
Fabi, S. G., Yoo, J. Y., Kaufman-Janette, J. A., Dayan, S., Boyd, C., Sangha, S., & Ashourian, N. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005166 · Cited by 10
Khachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Levi, J., Cross, S. H., Ramesh, N., et al. (2026) · medRxiv · doi:10.64898/2026.03.04.26347508 · Cited by 3
Therapeutic Considerations in Preventing Chronic Kidney Disease
Nicholas, S. B., Nobakht, N., & Alicic, R. Z. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-013325 · Cited by 2
Pastor, P. L., Amin, A., Galvan, D. L., Vasquez, O. N., Almandoz, J. P., & Lingvay, I. (2024) · Obesity Science & Practice · doi:10.1002/osp4.755 · Cited by 2
Self-citationKaiser, A. M., Carmichael, H., Lee, L., Aminpour, N., Alkhamesi, N. A., Ore, A. S., Dantu, S., Bonilla, E. J., deBeche-Adams, T., Krane, M. K., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-12878-3 · Cited by 2
Basta, D., Refaei, A. H. A., Msinjili, L., Frishman, W. H., & Lebovics, E. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001298 · Cited by 3
Henao, D. C., Jurado‐Florez, M. A., & Múñoz, Ó. (2024) · Obesity Science & Practice · doi:10.1002/osp4.782 · Cited by 2
SECTM1 Regulates Monocyte Levels and Is Associated With Incident Coronary Heart Disease
Tahir, U. A., Cruz, D. E., Shen, D., Tiwari, G., Liu, J., Huber, M. P., Chan, C. T., Deng, S., Benson, M. D., Robbins, J., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101378 · Cited by 4
Daniel, E., El-Nayir, M., Ogunniyi, K. E., Patel, Y. B., Olayiwola, P., Oredipe, O., Nwankwo, H., Nwaezeapu, K. I., & Ojo, T. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251393978 · Cited by 5
“8 The trial demonstrated that semaglutide significantly reduced the risk of MACE in patients with obesity, showing a 20% reduction in the primary composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction.”
InfluentialZufry, H., & Hariyanto, T. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70073 · Cited by 2
Obesidad, el papel del gastroenterólogo
Costa, V. A., Escobar, D. C., Kerguelen, A., Rodriguez, J., Rodriguez, A., & Neto, M. G. (2024) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.1192 · Cited by 2
Sattar, N. A., Lee, C. J., Srinath, R., Schauer, P. R., Wang, H., Falcón, B. L., HE, X., Stefański, A., & Plat, A. W. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101454 · Cited by 6
“Additionally, there is evidence that an approved treatment for obesity reduces the risk of atherosclerotic cardiovascular disease [10].”
Bantham, A., Hosking, M., & Rogers, R. J. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251335507d · Cited by 3
Optimizing outcomes from cardiac resynchronization therapy: what do recent data and insights say?
de Vere, F., Wijesuriya, N., Howell, S., Elliott, M. K., Mehta, V. S., Mannakkara, N. N., Strocchi, M., Niederer, S., & Rinaldi, C. A. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2445246 · Cited by 4
Cardiovascular outcome with SGLT2i and GLP1RA
Lim, S. K., Sohn, M., & Nauck, M. A. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.05.030 · Cited by 2
Ko, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
“9 Subsequently, the effects of semaglutide have also been shown to reduce major adverse cardiovascular events 10 and have recently been shown to improve liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).”
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Belančić, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70130 · Cited by 3
Bonga, K. N., & Padhan, M. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10565 · Cited by 2
Rational approaches to the treatment of patients with overweight and obesity: a cardiologist’s view
Miklishanskaya, S. V., & Mazur, N. A. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3087 · Cited by 2
Saraste, A., & Knuuti, J. M. (2026) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2026.102652 · Cited by 2
Spagnolo, M., & Capodanno, D. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf358 · Cited by 2
Zhu, D., & Herrington, W. G. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-02459-jc · Cited by 2
The Transformative Impact of New Anti-Obesity Medications: A Paradigm Shift in Medical Practice?
Sharma, A. M. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23078 · Cited by 3
A New Epoch in Treating Diseases of the Heart
Purnell, J. Q., & Camacho, S. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.007 · Cited by 2
Contemporary outcomes of carotid revascularization procedures
Park, J., John, E. S., Darling, J. D., & Schermerhorn, M. L. (2026) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2026.01.003 · Cited by 2
Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom
Ko, S., Domínguez, L., Ottaway, Z. V., Campbell, L. J., Fox, J., Burns, F. M., Hamzah, L., Ustianowski, A., Clarke, A. E., Kegg, S., et al. (2024) · HIV Medicine · doi:10.1111/hiv.13706 · Cited by 1
Harbi, M. H., Ashour, A. M., Alorfi, N. M., Aldurdunji, M. M., Wali, S. M., & Alzahrani, Y. A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1764664 · Cited by 4
Damhof, M., van Bruggen, F. V., & van Roon, E. V. (2026) · Diabetes, obesity and metabolism · doi:10.1111/dom.71075 · Cited by 2
“In addition to substantial weight loss, these agents improve cardiometabolic risk factors, including glycaemic control, blood pressure and lipid profiles, and have been associated with reductions in major cardiovascular events in selected populations [3, 4].”
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2024
Bhatt, H. V., Fritz, A. V., Feinman, J. W., Subramani, S., Malhotra, A. K., Townsley, M. M., Weiner, M. M., Sharma, A., Teixeira, M. T., Nguyen, B., et al. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.10.030 · Cited by 3
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 3
GLP-1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum Periods
Porterfield, F., Ogunwole, S. M., Maya, J., & Stanford, F. C. (2026) · Pediatric Drugs · doi:10.1007/s40272-026-00746-5 · Cited by 3
Semaglutide—a new treatment for obesity-related heart failure with preserved ejection fraction?
Donal, E., L'Official, G., & Istrătoaie, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00653-6 · Cited by 4
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Li, J., Mohamed, B. A., Huang, S., & Peng, Y. G. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2494646 · Cited by 3
Navaux, E., La, C., Dufour, S., Huberty, V., Mourabit, Y., Caës, T., Koliakos, N. N., Mikhalski, D., Moine, A. L., & Catalano, C. (2025) · Frontiers in Transplantation · doi:10.3389/frtra.2025.1623096 · Cited by 6
Iwasaki, Y., Shimada, T., Kishimori, T., Kato, T., Koike, J., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113072 · Cited by 2
Gabe, M. B. N., Fuhr, R., Sinn, A., Eliasen, A., Berthelsen, K. K., Kuhlman, A. B., Bækdal, T. A., & Nejad, A. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15951 · Cited by 3
Patient Experiences With GLP-1 Receptor Agonists
Hunt, I. D. V., Ramírez‐Posada, M., Babu, C., Brown‐Johnson, C. G., Linos, E., & Rodríguez, F. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.16951 · Cited by 6
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 2
“Similarly, RCTs have demonstrated that the GLP-1 agonist, semaglutide, reduces cardiovascular event risk by 20% as compared to results from the SAVE trial, where CPAP increased cardiovascular risk by 10% [46, 47].”
Alebna, P. L., Martey, S., Mehta, A., Lavie, C. J., & Carbone, S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02333-5 · Cited by 3
“In the SELECT trial [47], which evaluated semaglutide in individuals without diabetes, the curves for CVD outcomes, such as HFH and health status measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) began to separate early, prior to the onset of substantial weight differences between…”
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 3
Aliyeva, T., Natche, J., Jiakponna, E. C., Ahmad, F., Eze, B., Nawaz, U. H., El-Amri, I., & Shrestha, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01801-7 · Cited by 4
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
“16,92,106,107 Moreover, tirzepatide reduces cardiovascular death or decompensated HF by approaching 40% in patients with obesity and HFpEF.”
The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review
Corcoran, E., Kettlety, M., Mogul, U., Azah, J. N., & Cork, S. C. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104091 · Cited by 6
Elbashir, R. M. A., Elbashir, A., Basake, R. U., Mohieldin, A. Z. A., Elhaj, N. A. E., Ebrahim, F. E. M., Ahmed, W. G., & Mahgoub, O. A. M. (2025) · Cureus · doi:10.7759/cureus.95938 · Cited by 3
“Reductions in abdominal adiposity are particularly important given the close relationship between central obesity, metabolic syndrome, and cardiovascular risk [13].”
Reddy, Y. N. V., DeFranco, S., Lerman, A., Demmer, R. T., Chamberlain, A. M., Somers, V. K., & Borlaug, B. A. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.07.009 · Cited by 4
European survey on metabolic and cardiovascular risk in Cushing syndrome
Mondin, A., Barbot, M., Ceccato, F., Pereira, A. M., Angelousi, A. G., Elenkova, A. P., Žilaitienė, B., Schalin‐Jäntti, C., Herdt, C. D., Kanaka‐Gantenbein, C., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02663-9 · Cited by 3
New perspectives on semaglutide in cardiovascular disease
Seferovic, P. M., & Polovina, M. M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01734-9 · Cited by 2
Pham, M. H. X., Christensen, D. M., Kristensen, A. T., Middelfart, C., Sindet‐Pedersen, C., Gislason, G., & Olsen, N. T. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200299 · Cited by 5
Design Matters: How Methodological Decisions May Have Shaped the Findings of CREST-2
Chimowitz, M. I. (2026) · Stroke · doi:10.1161/strokeaha.125.054876 · Cited by 5
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
“Dedicated cardiovascular outcomes data for orforglipron are not yet available [52].”
Diagnosis and Management of Hypertension in Adolescents with Obesity
Chhabria, S. M., LeBron, J., Ronis, S. D., & Batt, C. E. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00740-x · Cited by 7
Beyond the Scale: Setting Goals for Outcomes Beyond Weight in Evidence-based Obesity Treatment
Schumacher, L. M., Hayes, J. F., Olson, K. L., Flanagan, S. P., Wohler, D., & Darling, K. E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00706-7 · Cited by 2
“This can be seen in data emerging from trials of newer OMMs [ 57 , 60 , 61 ], as well as the MBS literature [ 62 ].”
Ye, L., Tang, P., Wan, H., Zhong, X., Chen, X., Liu, C., & Huang, R. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s581491 · Cited by 3
“46 These findings support SEM’s potential use in treating heart injuries from inflammation.”
Acute renal infarction associated with Semaglutide (Ozempec) use
El-Reshaid, K., Al-Bader, A., & Abou-deeb, S. (2025) · International Journal of Case Reports and Images · doi:10.5348/101491z01ke2025cr · Cited by 2
The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management
Alvi, A., Singamala, H., Gadde, S. S. V., & Javvaji, C. K. (2026) · Cureus · doi:10.7759/cureus.100993 · Cited by 11
Barazzoni, R., Buscemi, S., Busetto, L., Sbraccia, P., Bo, S., Cereda, E., Chianelli, M., Chiappetta, S., Grave, R. D., Caro, W. D., et al. (2026) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-026-01813-z · Cited by 3
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
Treatment options for heart failure in individuals with overweight or obesity: a review
Nasoufidou, A., Stachteas, P., Karakasis, P., Kofos, C., Karagiannidis, E., Klisic, A. N., Popovic, D. S., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2479378 · Cited by 3
Management von Risikofaktoren und Begleiterkrankungen bei Vorhofflimmern
Gunawardene, M., & Schmidt, B. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2516-8410 · Cited by 2
Exploring the Molecular Pathology of Iatrogenic Amyloidosis
Bonilauri, B. (2024) · Journal of Molecular Pathology · doi:10.3390/jmp5020016 · Cited by 4
Shokravi, A., Seth, J., & Mancini, G. J. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03113-3 · Cited by 8
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., Udell, J. A., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.010 · Cited by 2
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
